Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial | VERU Stock NewsStockTitan·1 day ago, 04:17 AMVERU-3.88%RVMD+0.17%
Veru CEO Steiner to join Cantor Global Healthcare Conference fireside chatPUBT·Sep 2 at 12:32 PMVERU-3.88%
Divergent Capital Flows Reshape Secondary Assets as Southwest Hits Revenue RecordGlobal Report·Aug 27 at 10:14 AMAIOS-1.03%LUV+0.03%
Veru Chief Scientific Officer Gary Barnette acquires $4,841.82 in common sharesPUBT·Aug 17 at 08:26 PMVERU-3.88%
Pre-market hot trades in US stocks: Veru pre-market down 8.18%; USA Rare Earth pre-market down 7.20%Price Alert·Aug 11 at 10:13 AMVERU-3.88%USAR-3.40%
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial ProgressUnusual Whales·Aug 10 at 11:08 AMVERU-3.88%
Veru FY26 Q3 net loss narrows to $7 million; R&D expense rises 44% to $4.4 millionPUBT·Aug 10 at 10:30 AMVERU-3.88%
Veru wins US patent allowance for enobosarm-semaglutide weight-loss regimen claimsPUBT·Aug 4 at 12:35 PMVERU-3.88%
Veru schedules conference call on quarterly financial results and business updatePUBT·Aug 3 at 12:33 PMVERU-3.88%
